Global Genome-Based Drug Market Growth 2020-2025
COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.
According to this latest study, the 2020 growth of Genome-Based Drug will have significant change from previous year. By the most conservative estimates of global Genome-Based Drug market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. We give this scenario a XX% probability, where under the scenario the supply chain will start to recover and quarantines and travel bans will ease, over the Q2. Longer-term, the effect of COVID-19 will be felt throughout the year with some degree of harm done by the virus. Over the next five years the Genome-Based Drug market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2025.
This report presents a comprehensive overview, market shares, and growth opportunities of Genome-Based Drug market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Genome-Based Drug, covering the supply chain analysis, impact assessment to the Genome-Based Drug market size growth rate in several scenarios, and the measures to be undertaken by Genome-Based Drug companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Insulin
Growth Hormone
Monoclonal Antibody
Other
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Pharmaceutical Factory
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Sandoz International
Biosidus
Teva pharmaceutical industries
3SBio
Shanghai Fosun Pharmaceutical
Mylan
Reliance Life Sciences
Tonghua Dongbao Pharmaceutical
Probiomed
Biocon
AMEGA Biotech
Dong-A Pharmaceutical
LG Life Science
Celltrion
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Genome-Based Drug consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Genome-Based Drug market by identifying its various subsegments.
Focuses on the key global Genome-Based Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Genome-Based Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Genome-Based Drug submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 What is the Impact of Covid-19 Outbreak On the Genome-Based Drug?
1.8.1 Optimistic Scenario: COVID-19 Is Contained by May or June, with Normalcy Returning to Global Operations Through the End of Q2.
1.8.2 Conservative Scenario: COVID-19 Remains Prevalent, with Continued Impacts Lasting Into Q4.
1.8.3 Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Genome-Based Drug Market Size in 2020, by Scenario
1.8.4 Corporate Strategy the Manufacturers Should Be Thinking About Right Now
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Genome-Based Drug Consumption 2015-2025
2.1.2 Genome-Based Drug Consumption CAGR by Region
2.2 Genome-Based Drug Segment by Type
2.2.1 Insulin
2.2.2 Growth Hormone
2.2.3 Monoclonal Antibody
2.2.4 Other
2.3 Genome-Based Drug Consumption by Type
2.3.1 Global Genome-Based Drug Consumption Market Share by Type (2015-2020)
2.3.2 Global Genome-Based Drug Revenue and Market Share by Type (2015-2020)
2.3.3 Global Genome-Based Drug Sale Price by Type (2015-2020)
2.4 Genome-Based Drug Segment by Application
2.4.1 Hospital
2.4.2 Pharmaceutical Factory
2.4.3 Other
2.5 Genome-Based Drug Consumption by Application
2.5.1 Global Genome-Based Drug Consumption Market Share by Type (2015-2020)
2.5.2 Global Genome-Based Drug Value and Market Share by Type (2015-2020)
2.5.3 Global Genome-Based Drug Sale Price by Type (2015-2020)
3 Global Genome-Based Drug by Company
3.1 Global Genome-Based Drug Sales Market Share by Company
3.1.1 Global Genome-Based Drug Sales by Company (2018-2020)
3.1.2 Global Genome-Based Drug Sales Market Share by Company (2018-2020)
3.2 Global Genome-Based Drug Revenue Market Share by Company
3.2.1 Global Genome-Based Drug Revenue by Company (2018-2020)
3.2.2 Global Genome-Based Drug Revenue Market Share by Company (2018-2020)
3.3 Global Genome-Based Drug Sale Price by Company
3.4 Global Genome-Based Drug Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Genome-Based Drug Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Genome-Based Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Genome-Based Drug by Regions
4.1 Genome-Based Drug by Regions
4.2 Americas Genome-Based Drug Consumption Growth
4.3 APAC Genome-Based Drug Consumption Growth
4.4 Europe Genome-Based Drug Consumption Growth
4.5 Middle East & Africa Genome-Based Drug Consumption Growth
5 Americas
5.1 Americas Genome-Based Drug Consumption by Countries
5.1.1 Americas Genome-Based Drug Consumption by Countries (2015-2020)
5.1.2 Americas Genome-Based Drug Value by Countries (2015-2020)
5.2 Americas Genome-Based Drug Consumption by Type
5.3 Americas Genome-Based Drug Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Genome-Based Drug Consumption by Regions
6.1.1 APAC Genome-Based Drug Consumption by Regions (2015-2020)
6.1.2 APAC Genome-Based Drug Value by Regions (2015-2020)
6.2 APAC Genome-Based Drug Consumption by Type
6.3 APAC Genome-Based Drug Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Genome-Based Drug by Countries
7.1.1 Europe Genome-Based Drug Consumption by Countries (2015-2020)
7.1.2 Europe Genome-Based Drug Value by Countries (2015-2020)
7.2 Europe Genome-Based Drug Consumption by Type
7.3 Europe Genome-Based Drug Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Genome-Based Drug by Countries
8.1.1 Middle East & Africa Genome-Based Drug Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Genome-Based Drug Value by Countries (2015-2020)
8.2 Middle East & Africa Genome-Based Drug Consumption by Type
8.3 Middle East & Africa Genome-Based Drug Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Genome-Based Drug Distributors
10.3 Genome-Based Drug Customer
11 Global Genome-Based Drug Market Forecast
11.1 Global Genome-Based Drug Consumption Forecast (2021-2025)
11.2 Global Genome-Based Drug Forecast by Regions
11.2.1 Global Genome-Based Drug Forecast by Regions (2021-2025)
11.2.2 Global Genome-Based Drug Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Genome-Based Drug Forecast by Type
11.8 Global Genome-Based Drug Forecast by Application
12 Key Players Analysis
12.1 Sandoz International
12.1.1 Company Information
12.1.2 Genome-Based Drug Product Offered
12.1.3 Sandoz International Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Sandoz International Latest Developments
12.2 Biosidus
12.2.1 Company Information
12.2.2 Genome-Based Drug Product Offered
12.2.3 Biosidus Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Biosidus Latest Developments
12.3 Teva pharmaceutical industries
12.3.1 Company Information
12.3.2 Genome-Based Drug Product Offered
12.3.3 Teva pharmaceutical industries Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Teva pharmaceutical industries Latest Developments
12.4 3SBio
12.4.1 Company Information
12.4.2 Genome-Based Drug Product Offered
12.4.3 3SBio Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 3SBio Latest Developments
12.5 Shanghai Fosun Pharmaceutical
12.5.1 Company Information
12.5.2 Genome-Based Drug Product Offered
12.5.3 Shanghai Fosun Pharmaceutical Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Shanghai Fosun Pharmaceutical Latest Developments
12.6 Mylan
12.6.1 Company Information
12.6.2 Genome-Based Drug Product Offered
12.6.3 Mylan Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Mylan Latest Developments
12.7 Reliance Life Sciences
12.7.1 Company Information
12.7.2 Genome-Based Drug Product Offered
12.7.3 Reliance Life Sciences Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Reliance Life Sciences Latest Developments
12.8 Tonghua Dongbao Pharmaceutical
12.8.1 Company Information
12.8.2 Genome-Based Drug Product Offered
12.8.3 Tonghua Dongbao Pharmaceutical Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Tonghua Dongbao Pharmaceutical Latest Developments
12.9 Probiomed
12.9.1 Company Information
12.9.2 Genome-Based Drug Product Offered
12.9.3 Probiomed Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Probiomed Latest Developments
12.10 Biocon
12.10.1 Company Information
12.10.2 Genome-Based Drug Product Offered
12.10.3 Biocon Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Biocon Latest Developments
12.11 AMEGA Biotech
12.11.1 Company Information
12.11.2 Genome-Based Drug Product Offered
12.11.3 AMEGA Biotech Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 AMEGA Biotech Latest Developments
12.12 Dong-A Pharmaceutical
12.12.1 Company Information
12.12.2 Genome-Based Drug Product Offered
12.12.3 Dong-A Pharmaceutical Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.12.4 Main Business Overview
12.12.5 Dong-A Pharmaceutical Latest Developments
12.13 LG Life Science
12.13.1 Company Information
12.13.2 Genome-Based Drug Product Offered
12.13.3 LG Life Science Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.13.4 Main Business Overview
12.13.5 LG Life Science Latest Developments
12.14 Celltrion
12.14.1 Company Information
12.14.2 Genome-Based Drug Product Offered
12.14.3 Celltrion Genome-Based Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.14.4 Main Business Overview
12.14.5 Celltrion Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Genome-Based Drug Market Size in 2020, by Scenario
Table 2. COVID-19: Measures to be Undertaken by Genome-Based Drug Companies
Table 3. Research Methodology
Table 4. Data Source
Table 5. Genome-Based Drug Consumption CAGR by Region 2015-2025 ($ Millions)
Table 6. Major Players of Insulin
Table 7. Major Players of Growth Hormone
Table 8. Major Players of Monoclonal Antibody
Table 9. Major Players of Other
Table 10. Global Consumption Sales by Type (2015-2020)
Table 11. Global Genome-Based Drug Consumption Market Share by Type (2015-2020)
Table 12. Global Genome-Based Drug Revenue by Type (2015-2020) ($ million)
Table 13. Global Genome-Based Drug Value Market Share by Type (2015-2020) ($ Millions)
Table 14. Global Genome-Based Drug Sale Price by Type (2015-2020)
Table 15. Global Consumption Sales by Application (2015-2020)
Table 16. Global Genome-Based Drug Consumption Market Share by Application (2015-2020)
Table 17. Global Genome-Based Drug Value by Application (2015-2020)
Table 18. Global Genome-Based Drug Value Market Share by Application (2015-2020)
Table 19. Global Genome-Based Drug Sale Price by Application (2015-2020)
Table 20. Global Genome-Based Drug Sales by Company (2017-2019) (Kiloton)
Table 21. Global Genome-Based Drug Sales Market Share by Company (2017-2019)
Table 22. Global Genome-Based Drug Revenue by Company (2017-2019) ($ Millions)
Table 23. Global Genome-Based Drug Revenue Market Share by Company (2017-2019)
Table 24. Global Genome-Based Drug Sale Price by Company (2017-2019)
Table 25. Global Genome-Based Drug Manufacturing Base Distribution and Sales Area by Manufacturers
Table 26. Players Genome-Based Drug Products Offered
Table 27. Genome-Based Drug Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 28. Global Genome-Based Drug Consumption by Regions 2015-2020 (Kiloton)
Table 29. Global Genome-Based Drug Consumption Market Share by Regions 2015-2020
Table 30. Global Genome-Based Drug Value by Regions 2015-2020 ($ Millions)
Table 31. Global Genome-Based Drug Value Market Share by Regions 2015-2020
Table 32. Americas Genome-Based Drug Consumption by Countries (2015-2020) (Kiloton)
Table 33. Americas Genome-Based Drug Consumption Market Share by Countries (2015-2020)
Table 34. Americas Genome-Based Drug Value by Countries (2015-2020) ($ Millions)
Table 35. Americas Genome-Based Drug Value Market Share by Countries (2015-2020)
Table 36. Americas Genome-Based Drug Consumption by Type (2015-2020) (Kiloton)
Table 37. Americas Genome-Based Drug Consumption Market Share by Type (2015-2020)
Table 38. Americas Genome-Based Drug Consumption by Application (2015-2020) (Kiloton)
Table 39. Americas Genome-Based Drug Consumption Market Share by Application (2015-2020)
Table 40. APAC Genome-Based Drug Consumption by Countries (2015-2020) (Kiloton)
Table 41. APAC Genome-Based Drug Consumption Market Share by Countries (2015-2020)
Table 42. APAC Genome-Based Drug Value by Regions (2015-2020) ($ Millions)
Table 43. APAC Genome-Based Drug Value Market Share by Regions (2015-2020)
Table 44. APAC Genome-Based Drug Consumption by Type (2015-2020) (Kiloton)
Table 45. APAC Genome-Based Drug Consumption Market Share by Type (2015-2020)
Table 46. APAC Genome-Based Drug Consumption by Application (2015-2020) (Kiloton)
Table 47. APAC Genome-Based Drug Consumption Market Share by Application (2015-2020)
Table 48. Europe Genome-Based Drug Consumption by Countries (2015-2020) (Kiloton)
Table 49. Europe Genome-Based Drug Consumption Market Share by Countries (2015-2020)
Table 50. Europe Genome-Based Drug Value by Countries (2015-2020) ($ Millions)
Table 51. Europe Genome-Based Drug Value Market Share by Countries (2015-2020)
Table 52. Europe Genome-Based Drug Consumption by Type (2015-2020) (Kiloton)
Table 53. Europe Genome-Based Drug Consumption Market Share by Type (2015-2020)
Table 54. Europe Genome-Based Drug Consumption by Application (2015-2020) (Kiloton)
Table 55. Europe Genome-Based Drug Consumption Market Share by Application (2015-2020)
Table 56. Middle East & Africa Genome-Based Drug Consumption by Countries (2015-2020) (Kiloton)
Table 57. Middle East & Africa Genome-Based Drug Consumption Market Share by Countries (2015-2020)
Table 58. Middle East & Africa Genome-Based Drug Value by Countries (2015-2020) ($ Millions)
Table 59. Middle East & Africa Genome-Based Drug Value Market Share by Countries (2015-2020)
Table 60. Middle East & Africa Genome-Based Drug Consumption by Type (2015-2020) (Kiloton)
Table 61. Middle East & Africa Genome-Based Drug Consumption Market Share by Type (2015-2020)
Table 62. Middle East & Africa Genome-Based Drug Consumption by Application (2015-2020) (Kiloton)
Table 63. Middle East & Africa Genome-Based Drug Consumption Market Share by Application (2015-2020)
Table 64. Genome-Based Drug Distributors List
Table 65. Genome-Based Drug Customer List
Table 66. Global Genome-Based Drug Consumption Forecast by Countries (2021-2025) (Kiloton)
Table 67. Global Genome-Based Drug Consumption Market Forecast by Regions
Table 68. Global Genome-Based Drug Value Forecast by Countries (2021-2025) ($ Millions)
Table 69. Global Genome-Based Drug Value Market Share Forecast by Regions
Table 70. Global Genome-Based Drug Consumption Forecast by Type (2021-2025) (Kiloton)
Table 71. Global Genome-Based Drug Consumption Market Share Forecast by Type (2021-2025)
Table 72. Global Genome-Based Drug Value Forecast by Type (2021-2025) ($ Millions)
Table 73. Global Genome-Based Drug Value Market Share Forecast by Type (2021-2025)
Table 74. Global Genome-Based Drug Consumption Forecast by Application (2021-2025) (Kiloton)
Table 75. Global Genome-Based Drug Consumption Market Share Forecast by Application (2021-2025)
Table 76. Global Genome-Based Drug Value Forecast by Application (2021-2025) ($ Millions)
Table 77. Global Genome-Based Drug Value Market Share Forecast by Application (2021-2025)
Table 78. Sandoz International Product Offered
Table 79. Sandoz International Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2020E)
Table 80. Sandoz International Main Business
Table 81. Sandoz International Latest Developments
Table 82. Sandoz International Basic Information, Company Total Revenue (in $ million), Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 83. Biosidus Product Offered
Table 84. Biosidus Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2020E)
Table 85. Biosidus Main Business
Table 86. Biosidus Latest Developments
Table 87. Biosidus Basic Information, Company Total Revenue (in $ million), Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 88. Teva pharmaceutical industries Product Offered
Table 89. Teva pharmaceutical industries Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2020E)
Table 90. Teva pharmaceutical industries Main Business
Table 91. Teva pharmaceutical industries Latest Developments
Table 92. Teva pharmaceutical industries Basic Information, Company Total Revenue (in $ million), Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 93. 3SBio Product Offered
Table 94. 3SBio Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2020E)
Table 95. 3SBio Main Business
Table 96. 3SBio Latest Developments
Table 97. 3SBio Basic Information, Company Total Revenue (in $ million), Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 98. Shanghai Fosun Pharmaceutical Product Offered
Table 99. Shanghai Fosun Pharmaceutical Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2020E)
Table 100. Shanghai Fosun Pharmaceutical Main Business
Table 101. Shanghai Fosun Pharmaceutical Latest Developments
Table 102. Shanghai Fosun Pharmaceutical Basic Information, Company Total Revenue (in $ million), Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 103. Mylan Product Offered
Table 104. Mylan Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2020E)
Table 105. Mylan Main Business
Table 106. Mylan Latest Developments
Table 107. Mylan Basic Information, Company Total Revenue (in $ million), Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 108. Reliance Life Sciences Product Offered
Table 109. Reliance Life Sciences Basic Information, Company Total Revenue (in $ million), Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 110. Reliance Life Sciences Main Business
Table 111. Reliance Life Sciences Latest Developments
Table 112. Reliance Life Sciences Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2020E)
Table 113. Tonghua Dongbao Pharmaceutical Product Offered
Table 114. Tonghua Dongbao Pharmaceutical Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2020E)
Table 115. Tonghua Dongbao Pharmaceutical Main Business
Table 116. Tonghua Dongbao Pharmaceutical Latest Developments
Table 117. Tonghua Dongbao Pharmaceutical Basic Information, Company Total Revenue (in $ million), Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 118. Probiomed Product Offered
Table 119. Probiomed Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2020E)
Table 120. Probiomed Main Business
Table 121. Probiomed Latest Developments
Table 122. Probiomed Basic Information, Company Total Revenue (in $ million), Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 123. Biocon Product Offered
Table 124. Biocon Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2020E)
Table 125. Biocon Main Business
Table 126. Biocon Latest Developments
Table 127. Biocon Basic Information, Company Total Revenue (in $ million), Genome-Based Drug Manufacturing Base, Sales Area and Its Competitors
Table 128. AMEGA Biotech Product Offered
Table 129. AMEGA Biotech Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2020E)
Table 130. AMEGA Biotech Main Business
Table 131. AMEGA Biotech Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 132. AMEGA Biotech Latest Developments
Table 133. Dong-A Pharmaceutical Product Offered
Table 134. Dong-A Pharmaceutical Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2020E)
Table 135. Dong-A Pharmaceutical Main Business
Table 136. Dong-A Pharmaceutical Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 137. Dong-A Pharmaceutical Latest Developments
Table 138. LG Life Science Product Offered
Table 139. LG Life Science Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2020E)
Table 140. LG Life Science Main Business
Table 141. LG Life Science Latest Developments
Table 142. LG Life Science Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 143. Celltrion Product Offered
Table 144. Celltrion Genome-Based Drug Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2020E)
Table 145. Celltrion Main Business
Table 146. Celltrion Latest Developments
Table 147. Celltrion Basic Information, Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Genome-Based Drug
Figure 2. Genome-Based Drug Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Genome-Based Drug Consumption Growth Rate 2015-2025 (Kiloton)
Figure 5. Global Genome-Based Drug Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Insulin
Figure 7. Product Picture of Growth Hormone
Figure 8. Product Picture of Monoclonal Antibody
Figure 9. Product Picture of Other
Figure 10. Global Genome-Based Drug Consumption Market Share by Type (2015-2020)
Figure 11. Global Genome-Based Drug Value Market Share by Type (2015-2020)
Figure 12. Genome-Based Drug Consumed in Hospital
Figure 13. Global Genome-Based Drug Market: Hospital (2015-2020) (Kiloton)
Figure 14. Global Genome-Based Drug Market: Hospital (2015-2020) ($ Millions)
Figure 15. Genome-Based Drug Consumed in Pharmaceutical Factory
Figure 16. Global Genome-Based Drug Market: Pharmaceutical Factory (2015-2020) (Kiloton)
Figure 17. Global Genome-Based Drug Market: Pharmaceutical Factory (2015-2020) ($ Millions)
Figure 18. Genome-Based Drug Consumed in Other
Figure 19. Global Genome-Based Drug Market: Other (2015-2020) (Kiloton)
Figure 20. Global Genome-Based Drug Market: Other (2015-2020) ($ Millions)
Figure 21. Global Genome-Based Drug Consumption Market Share by Application (2015-2020)
Figure 22. Global Genome-Based Drug Value Market Share by Application (2015-2020)
Figure 23. Global Genome-Based Drug Sales Market Share by Company in 2017
Figure 24. Global Genome-Based Drug Sales Market Share by Company in 2019
Figure 25. Global Genome-Based Drug Revenue Market Share by Company in 2017
Figure 26. Global Genome-Based Drug Revenue Market Share by Company in 2019
Figure 27. Global Genome-Based Drug Sale Price by Company in 2019
Figure 28. Global Genome-Based Drug Consumption Market Share by Regions 2015-2020
Figure 29. Global Genome-Based Drug Value Market Share by Regions 2015-2020
Figure 30. Americas Genome-Based Drug Consumption 2015-2020 (Kiloton)
Figure 31. Americas Genome-Based Drug Value 2015-2020 ($ Millions)
Figure 32. APAC Genome-Based Drug Consumption 2015-2020 (Kiloton)
Figure 33. APAC Genome-Based Drug Value 2015-2020 ($ Millions)
Figure 34. Europe Genome-Based Drug Consumption 2015-2020 (Kiloton)
Figure 35. Europe Genome-Based Drug Value 2015-2020 ($ Millions)
Figure 36. Middle East & Africa Genome-Based Drug Consumption 2015-2020 (Kiloton)
Figure 37. Middle East & Africa Genome-Based Drug Value 2015-2020 ($ Millions)
Figure 38. Americas Genome-Based Drug Consumption Market Share by Countries in 2019
Figure 39. Americas Genome-Based Drug Value Market Share by Countries in 2019
Figure 40. Americas Genome-Based Drug Consumption Market Share by Type in 2019
Figure 41. Americas Genome-Based Drug Consumption Market Share by Application in 2019
Figure 42. United States Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 43. United States Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 44. Canada Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 45. Canada Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 46. Mexico Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 47. Mexico Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 48. APAC Genome-Based Drug Consumption Market Share by Countries in 2019
Figure 49. APAC Genome-Based Drug Value Market Share by Regions in 2019
Figure 50. APAC Genome-Based Drug Consumption Market Share by Type in 2019
Figure 51. APAC Genome-Based Drug Consumption Market Share by Application in 2019
Figure 52. China Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 53. China Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 54. Japan Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 55. Japan Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 56. Korea Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 57. Korea Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 58. Southeast Asia Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 59. Southeast Asia Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 60. India Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 61. India Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 62. Australia Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 63. Australia Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 64. Europe Genome-Based Drug Consumption Market Share by Countries in 2019
Figure 65. Europe Genome-Based Drug Value Market Share by Countries in 2019
Figure 66. Europe Genome-Based Drug Consumption Market Share by Type in 2019
Figure 67. Europe Genome-Based Drug Consumption Market Share by Application in 2019
Figure 68. Germany Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 69. Germany Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 70. France Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 71. France Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 72. UK Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 73. UK Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 74. Italy Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 75. Italy Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 76. Russia Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 77. Russia Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 78. Middle East & Africa Genome-Based Drug Consumption Market Share by Countries in 2019
Figure 79. Middle East & Africa Genome-Based Drug Value Market Share by Countries in 2019
Figure 80. Middle East & Africa Genome-Based Drug Consumption Market Share by Type in 2019
Figure 81. Middle East & Africa Genome-Based Drug Consumption Market Share by Application in 2019
Figure 82. Egypt Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 83. Egypt Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 84. South Africa Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 85. South Africa Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 86. Israel Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 87. Israel Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 88. Turkey Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 89. Turkey Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 90. GCC Countries Genome-Based Drug Consumption Growth 2015-2020 (Kiloton)
Figure 91. GCC Countries Genome-Based Drug Value Growth 2015-2020 ($ Millions)
Figure 92. Global Genome-Based Drug Consumption Growth Rate Forecast (2021-2025) (Kiloton)
Figure 93. Global Genome-Based Drug Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 94. Americas Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 95. Americas Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 96. APAC Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 97. APAC Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 98. Europe Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 99. Europe Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 100. Middle East & Africa Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 101. Middle East & Africa Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 102. United States Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 103. United States Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 104. Canada Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 105. Canada Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 106. Mexico Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 107. Mexico Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 108. Brazil Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 109. Brazil Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 110. China Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 111. China Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 112. Japan Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 113. Japan Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 114. Korea Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 115. Korea Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 116. Southeast Asia Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 117. Southeast Asia Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 118. India Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 119. India Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 120. Australia Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 121. Australia Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 122. Germany Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 123. Germany Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 124. France Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 125. France Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 126. UK Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 127. UK Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 128. Italy Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 129. Italy Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 130. Russia Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 131. Russia Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 132. Spain Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 133. Spain Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 134. Egypt Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 135. Egypt Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 136. South Africa Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 137. South Africa Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 138. Israel Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 139. Israel Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 140. Turkey Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 141. Turkey Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 142. GCC Countries Genome-Based Drug Consumption 2021-2025 (Kiloton)
Figure 143. GCC Countries Genome-Based Drug Value 2021-2025 ($ Millions)
Figure 144. Sandoz International Genome-Based Drug Market Share (2018-2020)
Figure 145. Biosidus Genome-Based Drug Market Share (2018-2020)
Figure 146. Teva pharmaceutical industries Genome-Based Drug Market Share (2018-2020)
Figure 147. 3SBio Genome-Based Drug Market Share (2018-2020)
Figure 148. Shanghai Fosun Pharmaceutical Genome-Based Drug Market Share (2018-2020)
Figure 149. Mylan Genome-Based Drug Market Share (2018-2020)
Figure 150. Reliance Life Sciences Genome-Based Drug Market Share (2018-2020)
Figure 151. Tonghua Dongbao Pharmaceutical Genome-Based Drug Market Share (2018-2020)
Figure 152. Probiomed Genome-Based Drug Market Share (2018-2020)
Figure 153. Biocon Genome-Based Drug Market Share (2018-2020)
Figure 154. AMEGA Biotech Genome-Based Drug Market Share (2018-2020)
Figure 155. Dong-A Pharmaceutical Genome-Based Drug Market Share (2018-2020)
Figure 156. LG Life Science Genome-Based Drug Market Share (2018-2020)
Figure 157. Celltrion Genome-Based Drug Market Share (2018-2020)
